

Nanion's SyncroPatch 96 validated with various targets and cells

Munich, Germany, April 14, 2009; The SyncroPatch 96, a high quality, high throughput patch clamp ion channel screening platform, shows impressive results with a wide variety of ion channels targets and cell lines.

The SyncroPatch 96 was displayed for the first time at the Biophysical Society Meeting in Boston, raising great interest within the pharma industry because of its vastly increased throughput and enabling features. The platform has continually been validated with various cell lines and ion channels of interest for the industrial-type ion channel HTS setting, with the aim of verifying the function and efficiency of the platform.

"The SyncroPatch 96 shows consistent success rates for all cell lines tested so far, including cell lines like HEK293, CHO, RBL and Jurkat. We have obtained success rates of approximately 60% for stable whole cell recordings, with Giga-Ohm seals. In addition, we tested both voltage and ligand gated ion channels, such as, Nav1.5, hERG, GABA_A and TRPV1. It works great!" states Dr. Andrea Brüggemann, CSO of Nanion Technologies.

The gathered experience in the development of the previous platforms, the Port-a-Patch and the Patchliner, has substantially sped up the work with the SyncroPatch 96. Michael George, CTO of Nanion says:

"The product development of the new instrument was initiated merely a year ago, and soon after, the first working prototype was rapidly generated. Thanks to our previous knowledge in developing complex and technically involved platforms, we'll soon be delivering a state-of-the art, fully-functional high-throughput screening platform such as the SyncroPatch 96. In addition, based on the proven success of our previous instruments, we are convinced that the SyncroPatch 96 will be a highly efficacious and an enabling tool for ion channel drug screening."

The SyncroPatch 96 will be commercially available by in the end of Q4, 2009. After the global release in Q4, the SyncroPatch 96 will be available for demonstrations at both our European and North American offices.

Our next exhibition of the SyncroPatch 96 is scheduled for the **Society of Bimolecular Screening Meeting**, in Lille, France, Apr. 26 – 30, 2009.

About Nanion:

Nanion Technologies GmbH is a German Private Limited Company and was founded in 2002 as a spin-off from the Center for Nanoscience (CeNS) of the University of Munich. Nanion's team has developed and globally established two highly successful automated patch clamp instruments as enabling tools for sophisticated and high throughput applications for ion channel research and drug discovery.

Nanion's instruments use planar patch clamp chips which replace the traditional glass pipette used in the technique of patch clamping. Nanion was nominated in 2007 for Germany's most prestigious innovation award the **Deutscher Zukunftspreis** (German Future Prize, Federal President's Award for Technology and Innovation).

Nanion recently opened its US office, in the "Heart of Pharma", North Brunswick, NJ, to support the rapidly growing number of American customers.



Contact details:

Dr. Niels Fertig, CEO, Phone: +49 89 2189 97972, Email: info@nanion.de, Web: www.nanion.de

Rodolfo Haedo, General Manager, Chief Applications Scientist of Nanion Technologies Inc.

Toll free number: 1-888-9-NANION, Email: info@naniontech.com, Web: www.naniontech.com